Skip to main content
. Author manuscript; available in PMC: 2024 Sep 14.
Published in final edited form as: J Med Chem. 2023 Aug 21;66(17):12249–12265. doi: 10.1021/acs.jmedchem.3c00806

Figure 3.

Figure 3.

In vivo antitumor activity of the compound 5d and its synergistic effect with immune checkpoint inhibitor. Mice bearing 4T1-Luc tumors were treated thrice per week with vehicle (DMSO/cremophor/normal saline = 5:5:90), 5d (10 mg/kg, i.p.), anti-PD-L1 (10 mg/kg, i.p.), or combination of 5d (10 mg/kg, i.p.), and anti-PD-L1 (10 mg/kg, i.p.). (A) Tumor volume and (B) body weight of the mice bearing 4T1-Luc tumors during administration. (C) Image of excised tumors from the mice and (D) their tumor weight. (E) Luciferase imaging (IVIS) of the mice on the final day of the experiment. Average signal intensity was measured by PerkinElmer Living Image software. *P < 0.05, **P < 0.01, ***P < 0.001 vs the control.